Fu Cangcang, Lin Nan, Zhu Jihua, Ye Qing
Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Vaccines (Basel). 2023 May 17;11(5):996. doi: 10.3390/vaccines11050996.
The objective of this study was to appraise the interrelation between overweight/obesity and the safety and efficacy of COVID-19 vaccination by synthesizing the currently available evidence.
A systematic review of published studies on the safety and efficacy of the COVID-19 vaccine in people who were overweight or obese was conducted. Databases including Embase, Medline Epub (Ovid), PsychInfo (Ovid), Web of Science, PubMed, CINAHL, and Google Scholar were searched to identify relevant studies. The databases of the Centers for Disease Control (CDC) and World Health Organization (WHO) were also searched for relevant unpublished and gray literature.
Fifteen studies were included in the review. All the included studies used observational study designs; there were ten cohort studies and five cross-sectional studies. The sample size of these studies ranged from 21 to 9,171,524. Thirteen studies reported using BNT162b2 (Pfizer-BioNTech, USA), four reported using ChAdOx-nCov19 (AstraZeneca, U.K), two were reported using CoronaVac (Sinovac, China), and two were reported using mRNA1273 (Moderna, USA). The efficacy and safety of COVID-19 vaccines have been extensively studied in individuals with overweight/obesity. Most studies have shown that the humoral response decreases with increasing BMI. The available evidence does not conclusively indicate that these vaccines are generally safe in this population.
While the efficacy of the COVID-19 vaccine may be less than ideal in people who are overweight or obese, it does not mean that obese people should not be vaccinated, as the vaccine can still provide some protection. There is a lack of evidence for conclusions to be drawn about the safety of the vaccine in the population. This study calls on health professionals, policymakers, caregivers, and all other stakeholders to focus on monitoring the possible adverse effects of injections in overweight/obese people.
本研究的目的是通过综合现有证据,评估超重/肥胖与新冠病毒疫苗接种的安全性和有效性之间的相互关系。
对已发表的关于超重或肥胖人群接种新冠病毒疫苗的安全性和有效性的研究进行系统综述。检索了包括Embase、Medline Epub(Ovid)、PsychInfo(Ovid)、Web of Science、PubMed、CINAHL和谷歌学术在内的数据库,以识别相关研究。还检索了疾病控制中心(CDC)和世界卫生组织(WHO)的数据库,以查找相关的未发表和灰色文献。
该综述纳入了15项研究。所有纳入的研究均采用观察性研究设计;其中有10项队列研究和5项横断面研究。这些研究的样本量从21到9,171,524不等。13项研究报告使用BNT162b2(美国辉瑞-生物科技公司),4项报告使用ChAdOx-nCov19(英国阿斯利康公司),2项报告使用科兴新冠疫苗(中国科兴公司),2项报告使用mRNA1273(美国莫德纳公司)。新冠病毒疫苗在超重/肥胖个体中的有效性和安全性已得到广泛研究。大多数研究表明,随着体重指数(BMI)的增加,体液反应会降低。现有证据并未确凿表明这些疫苗在该人群中普遍安全。
虽然新冠病毒疫苗在超重或肥胖人群中的有效性可能不太理想,但这并不意味着肥胖人群不应接种疫苗,因为疫苗仍可提供一定的保护。缺乏证据来得出关于该疫苗在人群中安全性的结论。本研究呼吁卫生专业人员、政策制定者、护理人员和所有其他利益相关者关注监测超重/肥胖人群接种疫苗可能产生的不良反应。